Others are not convinced by the results. “Surrogate virus is not the same,” says Vincent Raniello, a microbiologist at Columbia University in New York. Rachanillo points to the limitations of such studies and states that the evidence is currently insufficient to warrant testing of amodiaquine in humans.
In particular, when other researchers have run hamster and human-lung cell tests using hydroxychloroquine or chloroquine, they were evacuated. Just to be sure, Tenover and his colleagues also compared direct, head-to-head, amodiaquine and hydroxychloroquine in hamsters with a common control group. Amodiaquine reduced the amount of viral material. Did not hydroxychloroquine. (The experiment did not measure differences in living viruses.)
A malaria researcher at the Yale School of Public Health, Sunil Parikh, who is part of the trial of a different group of amodiaquine against Kovid-19, notes that the new study gave hamsters the drug the day after exposure to the pandemic The virus had gone. As a result, there is no way to know that an animal can be given medicine when it is already ill. “The results of the hamster model are impressive to demonstrate potential antimicrobial activity, but do not help to show any potential for healing,” says Parikh.
The intrigue of the new study results in Isaac Bogoche, a Toronto General Hospital Research Institute clinical investigator who specializes in infectious diseases. “I think it’s completely interesting,” he says. “But if the result is that people are taking amodiaquine and self-medicating, then the doctors claim that they have got the treatment, obviously this is the wrong answer, and we have done so before and Have done.
The hydroxychloroquine decibel underscores the profound dangers of hyping a drug in the absence of clinical trial data – not only for those who can receive a useless drug with potential side effects, but for those who have other reasons. Require that medication from. As the US government purchased reserves of hydroxychloroquine for use in the pandemic, and the number of prescriptions for it went through the roof as rumors spread about its potential use in the pandemic, which would have given patients such illnesses Lupus, who had been relying on treatment for years, started walking less. (This past spring, one of three Lupus patients said they had difficulty getting their pills.) With amodiaquine, the same stocking behavior can be even more destructive. It is used in the second most common combination treatment for malaria, a disease that claims the lives of about half a million people each year, most of whom are children in Africa under the age of five.
“If we have a condition like amodoquine as we had with hydroxychloroquine stockpiling, it is going to have a huge impact on countries seeking the necessary treatment for malaria, and potentially a huge impact in increasing malaria mortality.” Is, ”says Peter Olumsey, a medical officer in the World Health Organization’s Global Malaria Program. Amodiaquine is also given to healthy children in countries such as Nigeria and Chad to prevent malaria infection during the rainy season. In these conditions, the drug is usually given for three days per month. Last year, 20 million children received the drug.
There is another complication in the fact that amodoquine is not currently available in the US. Documents of liver damage among chronic users for the prevention of malaria in the 1980s; And there were also indications that when it accumulates in high amounts, the drug can cause abnormalities of the heart’s rhythm. Parikh says that complicates any possible use of amodiaquine as a preventive drug against Kovid-19. “Antimicrobial tests are quite challenging, and when amodiaquine was used as an antimicrobial in travelers to the west, it was drawn to toxicity,” he says.